|
| Press Releases |
|
 |
|
| Tuesday, October 3, 2023 |
|
|
HanchorBio Announces First Patient Dosed in the Phase 1 Multi-Regional Clinical Trial of HCB101 |
| more info >> |
|
| Monday, August 28, 2023 |
|
|
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies |
| HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies more info >> |
|
|
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies |
| HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies more info >> |
|
| Monday, July 24, 2023 |
|
|
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
| HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma. more info >> |
|
|
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
| HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma. more info >> |
|
| Monday, April 17, 2023 |
|
|
HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
| more info >> |
|
|
HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
| HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
マツダ、2025年度の参加型ブランド体験イベント「MAZDA FAN FESTA」の計画を発表
Feb 6, 2025 11:40: JST
|
|
|
Blackbox Press Event and Regional Government Roundtable
Feb 6, 2025 11:00 HKT/SGT
|
|
|
PT Lippo General Insurance Tbk (LGI) Unveils MyGo+: A Telematics-Based App for Safer Driving
Feb 6, 2025 08:30 HKT/SGT
|
|
|
Military Metals Appoints DGWA as European Financial Markets Advisor
Feb 5, 2025 21:39 HKT/SGT
|
|
|
Doubleview Gold Corp Increases the Dimensions of the Hat Polymetallic Deposit with High-Grade and Extensive Mineralization in Drill Holes H075 to H077
Feb 5, 2025 18:59 HKT/SGT
|
|
|
Approval in Principle (AiP) Acquired from Classification Society for Low-Pressure Type Coastal Liquefied CO2 Carrier
Feb 5, 2025 17:46 JST
|
|
|
富士通、世界最大のコネクティビティ関連展示会「MWC Barcelona 2025」に出展
Feb 5, 2025 14:30: JST
|
|
|
三菱造船、低圧液化CO₂内航輸送船の基本設計承認（AiP）を船級協会から取得
Feb 5, 2025 14:30: JST
|
|
|
トヨタ、米国ノースカロライナ州での車載用電池工場稼働開始
Feb 5, 2025 13:30: JST
|
|
|
トヨタ、上海市とカーボンニュートラルに関する包括的提携契約を締結
Feb 5, 2025 13:30: JST
|
|
|
トヨタ、2025年3月期 第3四半期決算を発表
Feb 5, 2025 13:30: JST
|
|
|
Toyota Powers On New North Carolina Automotive Battery Plant
Feb 5, 2025 13:59 JST
|
|
|
Toyota to Form Comprehensive Partnership on Carbon Neutrality with Shanghai and Establish a Company to Develop and Produce BEVs and Batteries
Feb 5, 2025 13:56 JST
|
|
|
Fujitsu to highlight AI-powered network technologies at MWC Barcelona 2025
Feb 5, 2025 10:25 JST
|
|
|
Mallia Therapeutics 與 Northway Biotech 宣布合作生產可溶性 CD83 蛋白 用於脫髮治療
Feb 5, 2025 08:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
